Business
ISAB: Revenue declined and losses increased, but FDA validation and new funding aim to drive growth
ISAB: Revenue declined and losses increased, but FDA validation and new funding aim to drive growth
About this update from Inhalation Sciences Sweden Ab
Revenue fell 37% to 11,047 tkr and net loss widened to -5,147 tkr, but cash remains stable and a 15.2 MSEK rights issue is planned to fund growth. FDA validation and new partnerships support future prospects. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
View stock analysis, news, and events for Inhalation Sciences Sweden Ab